Medicenna Therapeutics (MDNA) Corporate Presentation summary

Mission and strategic highlights

• Focused on developing life-changing immunotherapies for unmet medical needs, leveraging proprietary Superkine, BISKIT, and T-MASK platforms using directed evolution technology, which won the 2018 Nobel Prize in Chemistry.

• Pipeline includes early, mid, and late-stage assets targeting cancer and autoimmune/inflammatory diseases, with key collaborations and investments from Merck and RA Capital.

• Over 100 patients treated with lead candidates Bizaxofusp and MDNA11 to date.

Lead clinical programs and data

• MDNA11, a best-in-class IL-2 superkine, is in Phase 1/2 trials for advanced solid tumors, showing 30-50% ORR in checkpoint-resistant cancers and a favorable safety profile with no dose-limiting toxicities.

• Combination with KEYTRUDA® demonstrates clinical activity across multiple tumor types with historically low immunotherapy response rates, achieving a 36% ORR in eligible patients.

• Bizaxofusp, a first-in-class IL-4R targeted therapy for recurrent glioblastoma, doubled median overall survival to 14 months versus 7 months for matched controls and is Phase 3-ready.

Platform and pipeline innovation

• Superkine platform enables engineering of cytokines for enhanced pharmacology, tumor targeting, and conditional activation, supporting a robust pipeline including MDNA113 (anti-PD1 x IL-2 bispecific) and preclinical candidates for autoimmune and inflammatory diseases.

• MDNA113 is designed for tumor-specific targeting and conditional activation, with broad patent coverage and potential to address over 2 million patients annually with IL-13Ra2 positive cancers.